Viking Therapeutics (VKTX) Interest Coverage Ratio (2014 - 2026)
Viking Therapeutics (VKTX) reported Interest Coverage Ratio of 1.62 for Q1 2026, down 94.5% on a YoY basis from 29.54 in Q1 2025, and down 12.45% sequentially from 1.45 in Q4 2025.
Viking Therapeutics (VKTX) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Interest Coverage Ratio data on file, last reported at 1.62 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 94.5% year-over-year to 1.62; the trailing twelve-month figure through Mar 2026 stood at 4.97 (down 91.5% YoY), and the FY2025 full-year result was 3.45, down 275.08% from the prior year.
- Interest Coverage Ratio slipped to 1.62 in Q1 2026, from 1.45 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.0 in Q1 2023 to a low of 9.84 in Q2 2022.
- A 5-year average of 2.14 and a median of 0.84 in 2025 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio jumped 100.0% in 2023 and slumped 31826.29% in 2024, its largest moves.
- Tracing VKTX's Interest Coverage Ratio over 5 years: stood at 0.99 in 2022, then surged by 52.39% to 0.47 in 2023, then jumped by 30.48% to 0.33 in 2024, then plunged by 341.59% to 1.45 in 2025, then decreased by 12.45% to 1.62 in 2026.
- Business Quant data shows VKTX's Interest Coverage Ratio at 1.62 in Q1 2026, 1.45 in Q4 2025, and 1.31 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -1.63 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 |
| Dec 31, 2025 | -1.45 |
| Sep 30, 2025 | -1.31 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | -0.84 |
| Dec 31, 2024 | -0.33 |
| Sep 30, 2024 | -0.14 |
| Jun 30, 2024 | -0.15 |
| Mar 31, 2024 | -0.08 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -0.99 |
| Sep 30, 2022 | -9.19 |
| Jun 30, 2022 | -9.84 |
| Mar 31, 2022 | -9.07 |
| Dec 31, 2021 | -4.34 |
| Sep 30, 2021 | -2.41 |
| Jun 30, 2021 | -3.13 |